Inclusive of all taxes
SUNITCAP-Sunitinib Malate Capsules 50mg is a potent oral targeted anticancer therapy designed specifically for adult patients with advanced or metastatic cancers such as Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumors (GIST) post-imatinib failure, and unresectable or metastatic Pancreatic Neuroendocrine Tumors (pNETs). As a multi-targeted tyrosine kinase inhibitor (TKI), Sunitinib malate effectively obstructs key receptors responsible for tumor proliferation, angiogenesis, and the survival of cancer cells, thereby inhibiting disease progression and facilitating improved patient outcomes. This 50mg capsule formulation offers flexible dosing schedules including the standard 4 weeks on and 2 weeks off cycle or continuous dosing at reduced strengths to manage tolerability. Mandatory monitoring for side effects such as cardiac toxicity, hypertension, and liver function abnormalities ensures patient safety during treatment. SUNITCAP is a prescription-required oncology agent available via RADHAKRUSHNA MEDICALS with a minimal order quantity of one bottle, catering to hospitals, cancer care centers, and healthcare providers requiring factory-direct access for bulk procurement and export readiness.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Sunitinib Malate 50mg per capsule |
| Therapeutic Class | Multi-targeted Tyrosine Kinase Inhibitor (TKI) |
| Indications | Advanced RCC, GIST after imatinib failure, and metastatic or unresectable pNETs |
| Dosing Regimen | Standard: 50mg once daily for 4 weeks on, 2 weeks off; Alternative: 37.5mg once daily continuous |
| Side Effects Monitoring | Blood pressure, cardiac, thyroid, liver function regularly monitored |
| Prescription | Required |
| Packaging | Available in bottles |
| Minimum Order Quantity | 1 bottle |
| Manufacturer | Available via RADHAKRUSHNA MEDICALS |
| Attributes | Description |
|---|---|
| Dosage Form | Capsule |
| Strength | 50mg |
| Route of Administration | Oral |
| Indications | Advanced/Metastatic Renal Cell Carcinoma, GIST post-imatinib failure, Unresectable/Metastatic Pancreatic Neuroendocrine Tumors |
| Packaging Unit | Bottle |
| Storage Conditions | Store at room temperature, protect from moisture |
| Prescription Status | Prescription required |
| Treatment Cycle | 6 weeks (4 weeks on drug, 2 weeks off) or continuous dosing |
| Side Effects | Fatigue, diarrhea, nausea, hypertension, cardiac toxicity, thyroid dysfunction |
| Monitoring Requirements | Blood pressure, liver function, thyroid function, cardiac status |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
SUNITCAP is primarily indicated for advanced or metastatic Renal Cell Carcinoma (RCC), Gastrointestinal Stromal Tumors (GIST) after imatinib failure, and unresectable or metastatic Pancreatic Neuroendocrine Tumors (pNETs).
The standard dosing is 50mg once daily taken orally for 4 weeks followed by a 2-week drug-free period, making one complete treatment cycle of 6 weeks.
Yes, patients require regular monitoring of blood pressure, cardiac function, thyroid hormones, and liver function to detect and manage potential side effects.
Yes, dose reduction to 25mg or 12.5mg capsules can be implemented based on patient tolerance and toxicity.
Yes, this is a prescription-only anticancer medication and should be dispensed accordingly.
Country Of Origin: India
Inclusive of all taxes
You Save: 0
